Individualization of cancer therapy based on cytochrome P450 polymorphism: A pharmacogenetic approach

Cancer Treatment Reviews

Volumn 23, Issue 5-6, 1997, Pages 321-339

  Vermes, A ^a   Guchelaar, H J ^a   Koopmans, R P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZPHETAMINE; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; DAUNORUBICIN; DIAZEPAM; DICLOFENAC; DOXORUBICIN; DRUG METABOLIZING ENZYME; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HEXOBARBITAL; IFOSFAMIDE; IMIPRAMINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PHENACETIN; TAMOXIFEN; TENIPOSIDE; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER THERAPY; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; PHARMACOGENETICS;

EID: 0031460481     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90031-1     Document Type: Article

References (111)

1. Linder, M. W., Prough, R. A. & Valdes, R. Jr. (1997) Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43: 254-266.
2. May, D. G. (1994) Genetic differences in drug disposition. J. Clin. Pharmacol. 34: 881-897.
3. Ford, E. B. (1940) Polymorphism and taxonomy. In: Huxley, J., ed., The New Systematics. Oxford: Clarendon Press, pp. 493-573.
4. Smith, R. L. (1986) Human genetic variation in oxidative drug metabolism: introduction. Xenobiotica 16: 361-365.
5. Eichelbaum, M., Kroemer, H. K. & Mikes, G. (1992) Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol. Lett. 64/65: 115-122.
6. Meyer, U. A. & Zanger, U. M. (1977) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37: 269-296.
7. Nebert, D. W. (1991) Role of genetics and drug metabolism in human cancer risk. Mutation Research 247: 267-281.
8. Gonzalez, F. J. & Idle, J. R. (1994) Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 26: 59-70.
9. Kivistö, K. T., Kroemer, H. K. & Eichelbaum, M. (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40: 523-530.
10. Relling, M. V., Evans, W. E., Fonne-Pfister, R. & Meyer, U. A. (1989) Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver chromosomes. Cancer Res. 49: 68-71.
11. Lennard, L., Lilleyman, J. S., Van-Loon, J. & Weinshilboum, R. M. (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229.
12. Weinshilboum, R. M. (1992) Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 22: 1055-1071.
13. Le Guellec, C., Lacarelle, B., Catalin, J. & Durand, A. (1993) Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother. Pharmacol. 32: 491-495.
14. Coutts, R. T. (1994) Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J. Psychiatr. Neurosci. 19: 30-44.
15. DeVane, C. L. (1994) Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry 55 (12, Suppl.): 38-45.
16. Riesenman, C. (1995) Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 15: 84S-99S.
17. Nemeroff, C. B., DeVane, C. L. & Pollock, B. G. (1996) Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153: 311-320.
18. Miners, J., Birkett, D. J., Drew, D. & McManus, M. (1989) Microsomes and Drug Oxidations. London: Taylor and Francis, pp. 1-412.
19. Nebert, D. W. & Gonzalez, F. J. (1987) P450 genes: Structure, evolution and regulation. Annu. Rev. Biochem. 56: 945-993.
20. Schuster, I. (1989) Cytochrome P-450: Biochemistry and Biophysics. London: Taylor and Francis, pp. 1-92.
21. Guengerich, F. P. (1988) Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 48: 2946-2954.
22. Anonymous. (1996) Pharmacogenetics and the CYP2D6 polymorphism. ASCP 159-169.
23. Poulos, T. L., Finzel, B. C. & Howard, A. J. (1987) High-resolution crystal structure of cytochrome P450cam. J. Mol. Biol. 195: 687-700.
24. Black, S. D. (1993) Cytochrome P450 structure and function. In: Schenkman, J. B. & Greim, H., eds., Handbook of Experimental Pharmacology. Berlin: Springer, pp. 155-168.
25. Nelson, D. R., Kamataki, T., Waxman, D. J. et al. (1993) The P450 superfamily: update on new sequences, gene mapping, acession numbers, early trivial names of enzymes, and nomenclature. DNA Cell. Biol. 12: 1-51.
26. Daly, A. K., Brockmöller, J., Broly, F. et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201.
27. Nebert, D. W., Nelson, D. R., Adesnik, M. et al. (1989) The P450 gene superfamily. Update on the naming of new genes and nomenclature of chromosomal loci. DNA 8: 1-13.
28. Nebert, D. W., Nelson, D. R. & Feyereisen, R. (1989) Evolution of the cytochrome P450 genes. Xenobiotica 19: 1149-1160.
29. Nelson, D. R. & Strobel, H. W. (1987) Evolution of the cytochrome P450 proteins. Mol. Biol. Evol. 4: 572-593.
30. Gonzalez, F. J. & Nebert, D. W. (1990) Evolution of the P450 gene superfamily: Animal-plant 'warfare', molecular drive, and human genetic differences in drug oxidation. Trends Genet. 6: 182-186.
31. Gonzalez, F. J., Skoda, R. C., Dimura, S. et al. (1988) Characterization of the common genetic defect in humans deficient in debrisoquin metabolism. Nature 331: 442-446.
32. LLerna, A., Herraiz, A. G., Cobaleda, J., Johansson, I. & Dahl, M. L. (1993) Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 54: 606-611.
33. Madsen, H., Kramer Nielsen, K. & Brosen, K. (1995) Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms-a population study. Br. J. Clin. Pharmacol. 39: 433-439.
34. Corporaso, N., Tucker, M. A., Hoover, R. N. et al. (1990) Lung cancer and the debrisoquin metabolic phenotype. J. Natl. Cancer, Inst. 82: 1264-1274.
35. Rost, K. L., Brochmoller, J., Esdorn, F. & Roots, I. (1995) Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J. Hepatol. 23: 268-277.
36. Relling, M. V., Cherrie, J., Schell, M. J., Petros, W. P., Meyer, W. H. & Evans, W. E. (1991) Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmacol. Ther. 50: 308-313.
37. Bowie, L. J., Reddy, P. L., Nagabhushan, M. & Sevigny, P. (1994) Detection of Ó-thalassemias by multiplex polymerase chain reaction. Clin. Chem. 40: 2260-2266.
38. Sladek, N. E. (1971) Metabolism of cyclophosphamide by rat liver microsomes. Cancer Res. 31: 901-908.
39. Sladek, N. E. (1988) Metabolism of oxazaphosphorines. Pharmacol. Ther. 37: 301-355.
40. Clarke, L. & Waxman, D. J. (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49: 2344-2350.
41. Yule, S. M., Boddy, A. V., Cole, M. et al. (1995) Cyclophosphamide metabolism in children. Cancer Res. 55: 803-809.
42. Brade, W. P., Herdich, K. & Varini, M. (1985) Ifosfamide: pharmacology, safety and therapeutic potential. Cancer Treat. Rev. 12: 1-47.
43. Sarosy, G. (1989) Ifosfamide: pharmacological overview. Semin. Oncol. 16 (Suppl. 3): 2-8.
44. Weber, G. F. & Waxman, D. J. (1993) Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol. 45: 1685-1694.
45. Colvin, M. & Hilton, J. (1981) Pharmacology of cyclophosphamide and metabolites in man. Cancer Treat. Rev. 65 (Suppl. 3): 89-95.
46. Wrabetz, E., Peter, G. & Hohorst, H. J. (1980) Does acrolein contribute to the cytotoxicity of cyclophospamide. J. Cancer Res. Clin. Oncol. 98: 119-126.
47. Gurtoo, H. L., Marinello, A. J., Struck, R. F., Paul, B. & Dahms, R. P. (1981) Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites. J. Biol. Chem. 256: 11691-11701.
48. Chang, T. K. H., Weber, G. F., Crespi, C. L. & Waxman, D. J. (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53: 5629-5637.
49. Walker, D., Flinois, J.-P., Monkman, S. C. et al. (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 47: 1157-1163.
50. Goren, M. P., Wright, R. K., Pratt, C. B. & Pell, F. E. (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet. II: 1219-1220.
51. Ruzicka, J. A. & Ruenitz, P. C. (1992) Cytochrome P-450 mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug. Metab. Dispos. 20: 770-772.
52. Norpoth, N. (1976) Studies on the metabolism of cyclophosphamide (NSC-109724) in men. Cancer Treat. Rep. 60: 437-443.
53. Bohnenstengel, F., Hofmann, U., Eichelbaum, M. & Kroemer, H. K. (1996) Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophospamide in humans. Eur. J. Clin. Pharmacol. 51: 297-301.
54. Clark, P. I. & Slevin, M. L. (1987) The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12: 223-252.
55. Haim, N., Nemec, J., Roman, J. & Sinha, B. K. (1987) In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem. Pharmacol. 36: 527-536.
56. Evans, W. E., Sinkule, J. A., Crom, W. R., Dow, L. & Look, A. T. (1982) Pharmacokinetics of teniposide and etoposide in children with cancer. Cancer Chemother. Pharmacol. 7: 147-150.
57. Relling, M. V., Evans, R. Dass, C. Desiderio, D. M. & Nemec, J. (1992) Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther. 261: 491-496.
58. Haim, N., Nemec, J., Roman, J. & Sinha, B. K. (1986) Peroxidase free radical formation and O-demethylation of etoposide and teniposide. Biochem. Biophys. Res. Commun. 135: 215-220.
59. Haim, N., Nemec, J., Roman, J. & Sinha, B. K. (1987) Peroxidase-catalysed metabolism of etoposide and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res. 47: 5835-5840.
60. Harris, J. W., Rahman, A., Kim, B.-R., Guengerich, F. P. & Collins, J. M. (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54: 4026-4035.
61. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. & McPhail, A. T. (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93: 2325-2327.
62. Horwitz, S. B. (1992) Mechanism of action of taxol. Trends Pharmacol. Sci. 13: 134-136.
63. Guchelaar, H.-J., Ten Napel, C. H. H., de Vries, E. G. E. & Mulder, N. H. (1994) Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin. Oncol. 6: 40&-48.
64. James-Dow, C. A., Klecker, R. W., Katki, A. G. & Collins, J. M. (1995) Metabolism of taxol by human and rat liver in vitro: a screen for drug intractions and interspecies differences. Cancer Chemother. Pharmacol. 36: 107-114.
65. Monsarrat, B., Mariel, E., Cros, S. et al. (1990) Isolation and identification of three major metabolites of taxol in rat bile. Drug. Metab. Dispos. 18: 895-900.
66. Monsarrat, B., Alvinerie, P., Wright, M. et al. (1993) Hepatic metabolism and biliary excretion of taxol in rats and humans. Monogr. Natl. Cancer Inst. 15: 39-46.
67. Cresteil, T., Monsarrat, B., Alvinerie, P., Tréluyer, J. M., Vieira, I. & Wright, M. (1994) Taxol metabolism by human liver microsomes; identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 54: 386-392.
68. Harris, J. W., Katki, A., Anderson, L W., Chmurny, G. N., Paukstelis, J. V. & Collins, J. M. (1994) Isolation, structural determination and biological activity of 6α-hydroxytaxol, the principal human metabolite of taxol. J. Med. Chem. 37: 706-709.
69. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. & Harris, J. W. (1994) Selective biotransformation of taxol to 6α-hydrotaxol by human cytochrome P450 2C8. Cancer Res. 54: 5543-5546.
70. Kumar, G. N., Oatis, J. E. Jr, Thormberg, K. R., Heldich, F. J., Hazard, E. S. I. & Walle, T. (1994) 6α-Hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes. Drug Metab. Dispos. 22: 177-179.
71. Kumar, G. N., Walle, U. K. & Walle, T. (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J. Pharmacol. Exp. Ther. 268: 1160-1165.
72. Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A. & Relling, M. V. (1995) Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275: 566-575.
73. Walle, T., Walle, U. K., Kumar, G. N. and Bhalla, K. N. (1995) Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos. 23: 506-512.
74. Sonnichsen, D. S. & Relling, M. V. (1994) Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27: 256-269.
75. Gianni, L., Kearns, C. M., Giani, A. et al. (1995) Nonlinear pharmacolinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13: 180-190.
76. Smith, L. L. & White, I. N. H. (1995) Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Toxicol. Lett. 82/83: 181-186.
77. Jordan, V. C. (1988) The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat. 11: 197-208.
78. Baum, M. (1995) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer: Analysis at six years by Novadex Adjuvant Trial Organisation. Lancet. 1: 836-840.
79. Lerner, L. J. & Jordan, V. C. (1990) Development of antioestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res. 50: 4177-4189.
80. Catherino, W. H. & Jordan, V. C. (1993) A risk-benefit assessment of tamoxifen therapy. Drug Safety 8: 381-397.
81. Fisher, B. & Redmond, C. (1991) New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst. 83: 1278-1280.
82. Jordan, V. C. (1995) Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Ann. Rev. Pharmacol. Toxicol. 35: 195-211.
83. Dauplat, J., Le Bouedec, G. & Achard, J. L. (1990) Endometrial adenocarcinoma in 2 patients taking tamoxifen. Press. Med. 19: 380-381.
84. Killackey, M. A., Hakes, T. B. & Pierce, V. K. (1985) Endometrial adenocarcinoma in breast cancer patients receiving antietrogens. Cancer Treat. Rep. 69: 237-238.
85. Crewe, H. K., Ellis, S. W., Lennard, M. S. & Tucker, G. T. (1997) Variable contribution of cytochromes P4502D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53: 171-178.
86. Jacolot, F., Simon, I., Dreano, Y., Beaune, B., Riche, C., Berthou, F. (1991) Identification of the cytochrome P450IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41: 1911-1919.
87. Daniels, L., Blankson, E. A., Henderson, C. J. et al. (1992) Delineation of human cytochromes P450 involved in the metabolism of tamoxifen. Br. J. Clin. Pharmacol. 34: 153p-154p.
88. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. & Kupfer, D. (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21: 645-656.
89. Simon, I., Berthou, F., Riche, C., Beaune, P. & Ratanasavanh, D. (1993) Both cytochromes P4501A1 and 3A4 are involved in the demethylation of tamoxifen. Proceedings of the Fifth European ISSX Meeting, Tours, France, Abstract No 44.
90. 14]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol. 49: 1035-1042.
91. Hagen, B., Walseth, F., Walstad, R. A., Iversen, T. & Nilsen, O. G. (1987) Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Cancer Chemother. Pharmacol. 19: 143-148.
92. Hart, R. D., Perloff, M. & Holland, J. F. (1981) One-day VATH (vinblastine, Adriamycin, thiotepa, and Halosterin) therapy for advanced breast cancer refractory to chemotherapy. Cancer. 48: 1522-1527.
93. Veenema, R. J., Dean, A. L. Jr., Uson, A. C., Roberts, M. & Longo, F. (1969) Thiotepa bladder instillations: Therapy and prophylaxis for superficial bladder tumors. J. Urol. 101: 711-715.
94. Ng, S. & Waxman, D. J. (1993) Activation of thio-TEPA cytotoxicity toward human breast cancer cells by hepatic cytochrome P450. Int. J. Oncol. 2: 731-738.
95. Chang, T. K. H., Chen, G. & Waxman, D. J. (1995) Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalysed drug metabolism. J. Pharmacol. Exp. Ther. 274: 270-275.
96. Cohen, B. E., Egorin, M. J., Kohlhepp, E. A., Aisner, J. & Gutierrez, P. L. (1986) Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat. Rep. 70: 859-864.
97. Ng, S. & Waxman, D. J. (1990) Biotransformation of N,N′/N″-triethylenethiophosphoramide: oxidative desulfuration to yield N,N′N″-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P450-monooxygenase. Cancer Res. 50: 464-471.
98. Ng, S. & Waxman, D. J. (1991) N,N′N″-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. Cancer Res. 51: 2340-2345.
99. Strong, J. M., Collins, J. M., Lester, C. & Poplack, D. G. (1986) Pharmacokinetics of intraventricular and intravenous N,N′N″-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 46: 6101-6104.
100. Hagen, B., Dale, O., Neverdal, G., Arzi, S. & Nilson, O. G. (1991) Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation. Cancer Chemother. Pharmacol. 28: 441-447.
101. Teicher, B. A., Waxman, D. J., Holden, S. A. et al. (1989) Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitimour acitivty of N,N′N″-triethylenethiophosphoramide. Cancer Res. 49: 4996-5001.
102. 14C]thiotepa: Labeling of phosphatidyethanolamine. Cancer Res. 50: 4044-4049.
103. Zhou, X.-J., Martin, M., Placidi, M., Cano, J. P. & Rahmani, R. (1990) In vivo and in vitro pharmacokinetics and metabolism of vinca alkaloids in rat. II. Vinblastine and vincristine. Eur. J. Drug Metab. Pharmacokinet. 15: 323-332.
104. Zhou-Pan, X.-R., Sérée, E., Zhou, X.-J. et al. (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 53: 5121-5126.
105. Nelson, R. L., Dyke, R. W. & Root, M. A. (1980) Comparative pharmacokinetics of vindesine, Vincristine and vinblastine in patients with cancer. Cancer Treat. Rev. 7: 17-24.
106. Ratain, M. J., Vogelzang, N. J. & Sinkule, J. A. (1987) Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin. Pharmacol. Ther. 41: 61-67.
107. Zhou, X.-J., Zhou-Pan, X.-R., Gauthier, T., Placidi, M., Maurel, P. & Rahmani, R. (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem. Pharmacol. 45: 853-861.
108. Stupans, I., Richards, D. A. & McClure, M. T. (1995) Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica 25: 1-8.
109. 13C]-aminopyrine micro breath test. Eur. J. Drug. Metab. Pharmacokinet. 19: 119-124.
110. Lennard, L. (1992) The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43: 329-339.
111. Lennard, L., Lilleyman, J. S., Van Loon, L. & Weinshilboum, R. M. (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229.